Rational mucolytic therapy with ambroxol: controversial and indisputable. A review
- Authors: Babak S.L.1, Gorbunova M.V.1, Malyavin A.G.1
-
Affiliations:
- Yevdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 25, No 9 (2023): Otorhinolaryngology and pulmonology
- Pages: 623-628
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/253579
- DOI: https://doi.org/10.26442/20751753.2023.9.202405
- ID: 253579
Cite item
Full Text
Abstract
Many years of experience in the use of ambroxol is based on its ability to regulate the basic mechanisms of physiological production and transport of bronchial mucus. The main indication for ambroxol is the mucolytic therapy of acute and chronic bronchopulmonary diseases associated with hypersecretion and impaired mucus transport. Ambroxol has a number of the following properties: high secretolytic activity (promotes mucus clearance, facilitates expectoration of sputum, reduces productive cough); anti-inflammatory and antioxidant activity; local analgesic (anesthetic) effect through the blockade of sodium channels of cell membranes. The effect of anesthesia of the mucous membranes is attributed to the new pharmacological action of ambroxol, useful in the treatment of acute respiratory tract infections. The efficacy and safety of ambroxol in clinical practice has been confirmed by half a century of experience in its administration. The purpose of this publication was an up-to-date assessment of the controversial and indisputable chemical, pharmacological, clinical data on the properties of ambroxol in the concept of modern “recovery mucolytic therapy” that can improve the therapy and prognosis of patients with tracheobronchial secretion hypersecretion, impaired mucociliary clearance and unproductive cough.
Full Text
##article.viewOnOriginalSite##About the authors
Sergey L. Babak
Yevdokimov Moscow State University of Medicine and Dentistry
Author for correspondence.
Email: sergbabak@mail.ru
ORCID iD: 0000-0002-6571-1220
D. Sci. (Med.), Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation, MoscowMarina V. Gorbunova
Yevdokimov Moscow State University of Medicine and Dentistry
Email: mgorb@mail.ru
ORCID iD: 0000-0002-2039-0072
D. Sci. (Med.), Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation, MoscowAndrey G. Malyavin
Yevdokimov Moscow State University of Medicine and Dentistry
Email: maliavin@mail.ru
ORCID iD: 0000-0002-6128-5914
D. Sci. (Med.), Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation, MoscowReferences
- Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Effects of drugs on mucus clear-ance. Eur Respir.J. 1999;14(2):452-67.
- Зайцев А.А., Лещенко И.В., Эсаулова Н.А., Викторова И.А. Оценка эффективности и безопасности комбинированного препарата, содержащего амброксол, гвайфенезин и левосальбутамол, в сравнении с фиксированной комбинацией бромгексин/гвайфенезин/сальбутамол в терапии продуктивного кашля у взрослых пациентов с острым бронхитом. Терапевтический архив. 2023;95(3):236-42 [Zaitsev AA, Leshchenko IV, Esaulova NA, Viktorova IA. Evaluation of the efficacy and safety of a combination drug containing ambroxol, guaifenesin, and levosalbutamol versus a fixed-dose combination of bromhexine/guaifenesin/salbutamol in the treatment of productive cough in adult patients with acute bronchitis. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(3):236-24 (in Russian)]. doi: 10.26442/00403660.2023.03.202099
- Prevention of chronic bronchitis exacerbations with ambroxol (mucosolvan retard). An open, long-term, multicenter study in 5,635 patients. Respiration. 1989;55(Suppl.):84-96.
- Malerba M, Ponticiello A, Radaeli A, et al. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther. 2004;17(1):27-34. doi: 10.1016/j.pupt.2003.08.004
- Ratjen F, Wönne R, Posselt HG, et al. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr. 1985;144(4):374-8. doi: 10.1007/BF00441781
- Baranwal AK, Murthy AS, Singhi SC. High-dose Oral Ambroxol for Early Treatment of Pulmonary Acute Respiratory Distress Syndrome: an Exploratory, Randomized, Controlled Pilot Trial. J Trop Pediatr. 2015;61(5):339-50. doi: 10.1093/tropej/fmv033
- Aleksa VI, Prozorova VK, Mal'tseva NA, Shatikhina LN. Effectiveness of lasolvan in patients with chronic obstructive bronchitis and non-atopic bronchial asthma. Terapevticheskii Arkhiv (Ter. Arkh.). 2001;73(3):48-51.
- Шмелева Н.М. Мукорегулирующая терапия при заболеваниях органов дыхания: возможности амброксола. Consilium Medicum. 2012;14(11):7-11 [Shmeleva NM. Mukoreguliruyushchaia terapiia pri zabolevaniiakh organov dykhaniia: vozmozhnosti ambroksola. Consilium Medicum. 2012;14(11):7-11 (in Russian)].
- Cavalu S, Sharaf H, Saber S, et al. Ambroxol, a mucolytic agent, boosts HO-1, suppresses NF-κB, and decreases the susceptibility of the inflamed rat colon to apoptosis: A new treatment option for treating ulcerative colitis. FASEB J. 2022;36(9):e22496. doi: 10.1096/fj.202200749R
- Fegiz G. Prevention by ambroxol of bronchopulmonary complications after upper abdominal surgery: double-blind Italian multicenter clinical study versus placebo. Lung. 1991;169(2):69-76. doi: 10.1007/BF02714144
- Hashizume T. Pulmonary alveolar proteinosis successfully treated with ambroxol. Intern Med. 2002;41(12):1175-8. doi: 10.2169/internalmedicine.41.1175
- Yoshida S, Yokohira M, Yamakawa K, et al. Effects of the expectorant drug ambroxol hydrochloride on chemically induced lung inflammatory and neoplastic lesions in rodents. J Toxicol Pathol. 2018;31(4):255-65. doi: 10.1293/tox.2018-0012
- Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 2008;4(8):1119-29. doi: 10.1517/17425255.4.8.1119
- Guo Z, Chen Y, Ding X, et al. Simultaneous determination of ambroxol and salbutamol in human plasma by ultra-performance liquid chromatography-tandem mass spec-trometry and its application to a pharmacokinetic study. Biomed Chromatogr. 2016;30(11):1789-95. doi: 10.1002/bmc.3754
- Jauch R, Bozler G, Hammer R, et al. Ambroxol, studies of biotransformation in man and determination in biological samples (author's transl). Arzneimittelforschung. 1978;28(5a):904-11.
- Ishiguro N, Senda C, Kishimoto W, et al. Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes. Xenobiotica. 2000;30(1):71-80.
- Pueschmann S, Engelhorn R. Pharmacological study on the bromhexine metabolite am-broxol (author's transl). Arzneimittelforschung. 1978;28(5a):889-98.
- Miyata T, Kai H, Saito M, et al. Effects of am-broxol on pulmonary surfactant – analysis of the fatty acid composition of phosphatidylcho-line in the sputum and normal respiratory tract fluid in rabbits. Nihon Yakurigaku Zasshi. 1986;88(1):57-64.
- Kyle H, Robinson NP, Widdicombe JG. Mucus secretion by tracheas of ferret and dog. Eur J Respir Dis. 1987;70(1):14-22.
- IravaniJ, Melville GN. Mucociliary function of the respiratory tract as influenced by drugs. Respiration. 1974;31(4):350-7.
- Bossi R, Braga PC, Allegra L. Ambroxol and mucociliary transport. Arch Monaldi. 1984;39(3):227-33 (in Italian).
- Wirtz HR. Effect of ambroxol on surfactant secretion and synthesis in isolated type II alveolar cells. Pneumologie. 2000;54(7):278-83. doi: 10.1055/s-2000-4452
- Tahvanainen J, Hallman M. Surfactant abnormality after endotoxin-induced lung injury in guinea-pigs. Eur J Respir Dis. 1987;71(4):250-8.
- Dauberschmidt R, Kuckelt W, Bender V, et al. Effects of bromhexine metabolite VIII (NA 872) in an animal model of the respir-atory distress syndrome. Bull Eur Physiopathol Respir. 1980;16(2):135-43.
- Jang YY, Song JH, Shin YK, et al. Depressant effects of ambroxol and erdosteine on cytokine synthesis, granule enzyme release, and free radical production in rat alveolar macrophages activated by lipopolysaccharide. Pharmacol Toxicol. 2003;92(4):173-9.
- Ottonello L, Arduino N, Bertolotto M, et al. In vitro inhibition of human neutrophil histotoxicity by ambroxol: evidence for a multistep mechanism. Br J Pharmacol. 2003;140(4):736-42. doi: 10.1038/sj.bjp.0705497
- Fois G, Hobi N, Felder E, et al. A new role for an old drug: Ambroxol triggers lysosomal exocytosis via pH-dependent Ca² release from acidic Ca² stores. Cell Calcium. 2015;58(6):628-37. doi: 10.1016/j.ceca.2015.10.002
- Koyama I, Matsunaga T, Harada T, et al. Ambroxol reduces LPS toxicity mediated by induction of alkaline phosphatases in rat lung. Clin Biochem. 2004;37(8):688-93. doi: 10.1016/j.clinbiochem.2004.02.004
- Yang B, Yao DF, Ohuchi M, et al. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur Respir J. 2002;19(5):952-8.
- Leffler A, Reckzeh J, Nau C. Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol. 2010;630(1-3):19-28. doi: 10.1016/j.ejphar.2009.12.027
- Guerra-Farfan E, Garcia-Sanchez Y, Jornet-Gibert M, et al. Clinical practice guidelines: The good, the bad, and the ugly. Injury. 2023;54 Suppl. 3:S26-9. doi: 10.1016/j.injury.2022.01.047
- Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;5(5):CD001287. doi: 10.1002/14651858.CD001287.pub6
- Papadopoulou E, Hansel J, Lazar Z, et al. Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis. Eur Respir Rev. 2023;32(167):220141. doi: 10.1183/16000617.0141-2022
- Cazan D, Klimek L, Sperl A, et al. Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opin Drug Saf. 2018;17(12):1211-224. doi: 10.1080/14740338.2018.1533954
- Kantar A, Klimek L, Cazan D, et al. An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children. Multidiscip Respir Med. 2020;15(1):511. doi: 10.4081/mrm.2020.511